- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00757146
Neonatal Intensive Care (NICU) Course and Hospital Outcome of Infants With BPD Treated Using Inhaled Nitric Oxide
June 22, 2010 updated by: University of Utah
NICU Course and Hospital Outcome of Infants With Bronchopulmonary Dysplasia Treated Using Inhaled Nitric Oxide
This is a chart review study of neonates admitted to Primary Children's Medical Center or University of Utah NICU who had or developed a diagnosis of bronchopulmonary dysplasia (BPD) and were treated for this condition with inhaled nitric oxide (iNO) beginning after the 4th week of life.
For this study BPD will be defined as need for supplemental oxygen on day 28 of life.
The data collection from the medical record will gather demographics on admission (birth weight, gestational age, etc); past medical history from transferring hospitals; admission diagnoses; hospital respiratory care treatment course and laboratory/xray findings; nutrition and growth; and discharge diagnoses including all major neonatal morbidities such as absence or severity of intraventricular hemorrhage, retinopathy of prematurity, or hearing deficits.
The data will be compiled and compared to data previously published on similar infants with BPD but not treated with iNO.
Study Overview
Status
Completed
Conditions
Detailed Description
Recent studies (e.g.
Schreiber 2003)1 have prompted several large current clinical trials on the use of inhaled nitric oxide (iNO) for the prevention of bronchopulmonary dysplasia (BPD) in preterm infants.
Results of these studies are not yet published and will be forthcoming Spring 2006.
However, there is evidence to suggest that for patients with BPD, treatment with iNO may improve oxygenation2 and improve pulmonary blood flow by relaxing pulmonary vascular tone.
3 Also, there is a recent primate study that suggests in the face of existing BPD, treatment with iNO may decrease oxygen and ventilation requirements through a mechanism that helps preserve surfactant protein.4
Taken together, this preliminary work suggests there may be clinical benefit in treating established BPD with iNO.
However, as few data exist on the clinical course of BPD patients treated with iNO, further description is necessary to evaluate iNO as a potential treatment modality for BPD.
Since iNO has been used as adjunctive therapy for neonates at PCMC with serious respiratory disease, useful information on the relationship between BPD and iNO treatment may exist within our own patient population
Study Type
Observational
Enrollment (Actual)
18
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Univesity of Utah / Primary Childrens Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 4 weeks (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Any patient who at 28 days of life was requiring oxygen therapy in the Neonatal Intensive Care Unit and who was then treated with iNO would be eligible for chart review.
Since iNO therapy has only been available for a few years, this study will attempt to capture all patients who qualify.
Any patient who received iNO treatment under an IRB study protocol after 28d of life would not be eligible for chart review.
Description
Inclusion Criteria:
- Any patient who at 28 days of life was requiring oxygen therapy in the Neonatal Intensive Care Unit and who was then treated with iNO would be eligible for chart review. Since iNO therapy has only been available for a few years, this study will attempt to capture all patients who qualify.
Exclusion Criteria:
- Any patient who received iNO treatment under an IRB study protocol after 28d of life would not be eligible for chart review.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Gather descriptive information on the hospital course and outcome of infants treated with iNO who had a diagnosis of BPD.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Donald .Null, MD, University of Utah / Primary Childrens Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2006
Primary Completion (Actual)
February 1, 2010
Study Completion (Actual)
February 1, 2010
Study Registration Dates
First Submitted
September 19, 2008
First Submitted That Met QC Criteria
September 22, 2008
First Posted (Estimate)
September 23, 2008
Study Record Updates
Last Update Posted (Estimate)
June 24, 2010
Last Update Submitted That Met QC Criteria
June 22, 2010
Last Verified
June 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17091
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchopulmonary Dysplasia
-
Centre Hospitalier Intercommunal CreteilNot yet recruitingControls Born at Term | Premature With Dysplasia Bronchopulmonary | Premature Without Dysplasia Bronchopulmonary
-
Adel MohamedHealth Sciences Centre, Winnipeg, Manitoba; Mount Sinai Hospital, CanadaCompletedBronchopulmonary Dysplasia (BPD)Canada
-
Children's Hospital of PhiladelphiaCompleted
-
Cynthia McEvoyUniversity of Florida; University of California, San Francisco; Thrasher Research... and other collaboratorsCompletedBronchopulmonary Dysplasia (BPD)United States
-
Children's Hospital of Eastern OntarioThe Hospital for Sick Children; Hannover Medical School; MOUNT SINAI HOSPITAL; St... and other collaboratorsRecruitingLung Function | BPD - Bronchopulmonary DysplasiaCanada
-
Christoph HornikNational Heart, Lung, and Blood Institute (NHLBI); University of North Carolina...RecruitingBronchopulmonary Dysplasia of NewbornUnited States
-
Medipost Co Ltd.RecruitingSevere Bronchopulmonary DysplasiaKorea, Republic of
-
PediatrixPhoenix Children's Hospital; Banner HealthActive, not recruitingBPD - Bronchopulmonary DysplasiaUnited States
-
University of FloridaCompletedPreterm Infant | Barotrauma | BPD - Bronchopulmonary DysplasiaUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedBronchopulmonary Dysplasia; Retinopathy of PrematurityItaly